Inactive Instrument

Northwest Biotherapeutics, Inc Stock OTC Bulletin Board

US66737P5017

Biotechnology & Medical Research

End-of-day quote OTC Bulletin Board Other stock markets
- ^USD	-

Jul. 08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
May. 15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI

Valuation: Northwest Biotherapeutics, Inc

Market Cap	305M 268M 247M 228M 433M 29.22B 441M 2.97B 1.15B 14.3B 1.15B 1.12B 49.64B	P/E 2026 *	-	P/E 2027 *	-
Enterprise Value	401M 352M 325M 300M 569M 38.42B 580M 3.91B 1.52B 18.8B 1.51B 1.47B 65.27B	EV / Sales 2026 *	-	EV / Sales 2027 *	11x
Free-Float	95.04%	Yield 2026 *	-	Yield 2027 *	-

* Estimated data More valuation ratios

Latest news : Northwest Biotherapeutics, Inc

Jul. 08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of Dcvax-L for Glioblastoma	CI
May. 15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2026	CI
Apr. 21	Northwest Biotherapeutics Establishes Dedicated Leukapheresis Clinic	CI
Apr. 15	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Full Year Ended December 31, 2025	CI
Apr. 14	Northwest Biotherapeutics, Inc. Auditor Raises 'Going Concern' Doubt	CI
Nov. 14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2025	CI
Nov. 13	Northwest Biotherapeutics, Inc. announced that it expects to receive $4.75 million in funding from Yorkville Advisors Global LP	CI
25-10-31	Northwest Biotherapeutics, Inc. Enters into A Commercial Loan Agreement and Note with Streeterville Capital, LLC	CI
25-10-26	Northwest Biotherapeutics, Inc. announced that it has received $5.505 million in funding	CI
25-10-23	Northwest Biotherapeutics, Inc. completed the acquisition of Advent Bioservices Ltd from Toucan Holdings LLC.	CI
25-08-26	Northwest Biotherapeutics, Inc. entered into an agreement to acquire Advent Bioservices Ltd from Toucan Holdings LLC for £1.4 million.	CI
25-08-18	Northwest Biotherapeutics, Inc. Announces the Passing of Its Senior Vice President and General Counsel, Mr. Les Goldman	CI
25-08-14	Northwest Biotherapeutics, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2025	CI

More news

Press Releases: Northwest Biotherapeutics, Inc

Jul. 08	Northwest Biotherapeutics Presents Updated Survival Data from Phase III Trial of DCVax®-L For Glioblastoma Using Individual Patient Level Data in Multiple Independent Analyses	PR
Jul. 02	Northwest Biotherapeutics Announces Scientific Presentation on Propensity Score Matching at the British Neuro-Oncology Society Annual Meeting	PR
May. 15	Northwest Biotherapeutics: Q1 Earnings Snapshot	AQ
Apr. 30	Northwest Biotherapeutics Appoints Dr. Annalisa Jenkins As Strategic Adviser To Advance Dendritic Cell Cancer Vaccine Platform	PR
Apr. 21	Northwest Biotherapeutics Announces Establishment Of the Company's Own Dedicated Leukapheresis Clinic	PR

More press releases

Managers and Directors: Northwest Biotherapeutics, Inc

Manager	Title	Age	Since
Alton Boynton CEO	Chief Executive Officer	82	2007-05-31
Linda Powers CEO	Chief Executive Officer	71	2011-06-07
Marnix Bosch CTO	Chief Tech/Sci/R&D Officer	67	1999-12-31

Director	Title	Age	Since
Alton Boynton BRD	Director/Board Member	82	1997-12-31
Linda Powers CHM	Chairman	71	2007-05-16
Navid Malik BRD	Director/Board Member	57	2012-03-31

More insiders

Northwest Biotherapeutics, Inc. is a biotechnology company. The Company is focused on developing personalized immune therapies for cancer. It has developed a platform technology, DCVax, which uses activated dendritic cells to mobilize a patient's own immune system to attack their cancer. The Company's product line includes DCVax-L and DCVax-Direct. DCVax-L is designed to treat solid tumor cancers in which the tumors can be surgically removed. It has completed a 331-patient international Phase III trial of DCVax-L for Glioblastoma multiforme brain cancer (GBM). DCVax-Direct is designed to treat inoperable solid tumors. A 40-patient Phase I trial has been completed and includes treatment of a diverse range of more than a dozen types of cancers. Its subsidiaries include Flaskworks LLC, NW Bio GmbH, Northwest Biotherapeutics Capital Limited, Northwest Biotherapeutics B.V., Advent BioServices Ltd., and others.

Employees

Sector

Biotechnology & Medical Research

More about the company

Google lets you customize your preferred sources.

Choose MarketScreener

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
ARGENX SE	-0.43%	-3.44%	+71.35%	+126.62%	56.71B
WUXI APPTEC CO., LTD.	-2.45%	-7.83%	+63.92%	+83.15%	51.3B
INSMED INCORPORATED	+0.94%	+5.99%	+22.61%	+479.80%	25.26B
BIONTECH SE	+0.04%	-3.83%	-16.08%	-12.68%	23.65B
WUXI BIOLOGICS (CAYMAN) INC.	+3.93%	+7.11%	+44.20%	-1.96%	18.69B
GENMAB A/S	+2.01%	+2.56%	+40.14%	-24.77%	17.71B
PHARMAESSENTIA CORPORATION	-6.84%	+4.81%	+201.88%	+348.11%	17.7B
SICHUAN KELUN-BIOTECH BIOPHARMACEUTICAL CO., LTD.	-0.92%	+8.90%	+38.48%	-	14.26B
EXELIXIS, INC.	+1.24%	+2.07%	+29.35%	+198.93%	14.1B
Average	-0.27%	+3.18%	+55.10%	+149.65%	26.6B
Weighted average by Cap.	-0.54%	+1.64%	+56.77%	+141.06%

	2026 *	2027 *
Net sales	-	38.93M 34.15M 31.53M 29.13M 55.22M 3.73B 56.33M 379M 147M 1.82B 146M 143M 6.33B
Net income	-	-
Net Debt	96.08M 84.27M 77.8M 71.89M 136M 9.2B 139M 935M 363M 4.5B 361M 353M 15.63B	125M 110M 101M 93.49M 177M 11.96B 181M 1.22B 473M 5.85B 469M 459M 20.32B

Northwest Biotherapeutics, Inc Stock OTC Bulletin Board

Stocks

US66737P5017

Biotechnology & Medical Research

Valuation: Northwest Biotherapeutics, Inc

Latest news : Northwest Biotherapeutics, Inc

Press Releases: Northwest Biotherapeutics, Inc

Managers and Directors: Northwest Biotherapeutics, Inc

Bio Therapeutic Drugs

Financials

Company Profile